Background: Fentanyl test strips (FTS) are lateral flow immunoassay strips designed for detection of ng/mL levels of fentanyl in urine. In 2021, the US Centers for Disease Control and the Substance Abuse and Mental Health Administration stated that federal funds could be used for procurement of FTS for harm reduction strategies approved by the government such as drug checking. The market for FTS has expanded rapidly in the US and Canada. However, there is no regulatory oversight by either government to ensure proper function of FTS that are being marketed for drug checking.

Main Body: Many brands of FTS have rapidly entered the harm reduction market, creating concerns about the reproducibility and accuracy of their performance from brand to brand and lot to lot. Some examples are provided in this Comment. Similar problems with product quality were observed in the mid 2000's when lateral flow immunoassays for malaria were funded in many countries and again in 2020, when COVID-19 tests were in huge demand. The combination of high demand and low levels of regulation and enforcement led some manufacturers to join the goldrush without adequate field testing or quality assurance. We argue that the harm reduction community urgently needs to set a lot checking program in place. A set of simple protocols for conducting the tests and communicating the results have been developed, and are described in the following Perspectives paper in this issue.

Conclusion: In the absence of governmental regulation and enforcement, the harm reduction community should implement a FTS lot checking program. Based on previous experience with the malaria diagnostic lot checking program, this inexpensive effort could identify products that are not suitable for harm reduction applications and provide valuable feedback to manufacturers. Dissemination of the results will help harm reduction organizations to ensure that FTS they use for drug checking are fit for the purpose.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11179324PMC
http://dx.doi.org/10.1186/s12954-024-01025-7DOI Listing

Publication Analysis

Top Keywords

harm reduction
28
lateral flow
12
lot checking
12
checking program
12
fentanyl test
8
test strips
8
drug checking
8
regulation enforcement
8
reduction community
8
harm
7

Similar Publications

Introduction: Buprenorphine is a highly effective medication for opioid use disorder (MOUD; OUD), which can be prescribed alongside naloxone in the primary care setting as part of a harm reduction approach to OUD. Despite this potential, implementation challenges have limited adoption of MOUD. To address barriers at the organizational level, we need better tools to measure perceived organizational support for the treatment of OUD and use of MOUD in the primary care setting.

View Article and Find Full Text PDF

Different forms of stigma and rural primary care professionals' willingness to prescribe buprenorphine.

J Subst Use Addict Treat

January 2025

Gillings School of Global Public Health, University of North Carolina Chapel Hill, Chapel Hill, NC, United States of America. Electronic address:

Introduction: Buprenorphine and other medications for opioid use disorder (MOUD) are highly effective but substantially under prescribed in the rural United States. Among the most cited barriers to buprenorphine prescribing is stigma, yet little progress has been made in developing successful strategies to reduce stigma and increase access to life-saving medication. One of the key challenges to developing successful implementation strategies is understanding the different types of stigma that limit implementation.

View Article and Find Full Text PDF

The association of medical cannabis use with quality of life in Illinois' opioid alternative pilot program.

J Epidemiol Popul Health

January 2025

Northwestern University Feinberg School of Medicine, Chicago, IL, United States; Center of Innovation for Complex Chronic Healthcare, Hines VA Hospital, Hines, IL, United States.

Background: In Illinois, the Opioid Alternative Pilot Program (OAPP) was launched to expand access to medical cannabis to use as a direct substitute for opioids. Although therapeutic benefits have been reported in reducing opioid use, there is an absence of literature that examines how medical cannabis use impacts an individual's quality of life (QoL). This study examines the association of medical cannabis use with QoL among the first enrollees in OAPP.

View Article and Find Full Text PDF

The Rise of Fentanyl: Molecular Aspects and Forensic Investigations.

Int J Mol Sci

January 2025

Legal Medicine, Department of Medical, Surgical and Advanced Technologies "G.F. Ingrassia", University of Catania, 95123 Catania, Italy.

Fentanyl is a synthetic opioid widely used for its potent analgesic effects in chronic pain management and intraoperative anesthesia. However, its high potency, low cost, and accessibility have also made it a significant drug of abuse, contributing to the global opioid epidemic. This review aims to provide an in-depth analysis of fentanyl's medical applications, pharmacokinetics, metabolism, and pharmacogenetics while examining its adverse effects and forensic implications.

View Article and Find Full Text PDF

This study investigates the effects of social norms on substance use severity mediated by health beliefs among people who use cannabis, narcotics, and psychotropic substances in Republic of Korea. A survey was administered to 109 people who use cannabis and narcotics and 191 people who use psychotropic substances between May and July 2024. Path analysis was conducted.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!